Cellectis (CLLS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$57.2M

Revenue (quarter)

$6.9M

Revenue growth (year over year)

−62.05%

Gross profit (trailing twelve months)

$57.2M

Gross margin

100.00%

Net income (trailing twelve months)

−$65.3M

Net income (quarter)

−$21.8M

Net income growth (year over year)

+8.08%

Net margin

−114.23%

Return on equity

−94.54%

EPS (trailing twelve months)

−$0.64

Book value per share

$0.56

P/E (trailing twelve months)

—

Price to book

1.95

Debt to assets

84.64%

Payout ratio

—

Dividend yield

—

Company profile

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

• Is Cellectis (CLLS) profitable?

  No. Cellectis reported a net loss of $65.3M over the trailing twelve months.

• How much revenue does Cellectis (CLLS) make?

  Cellectis generated $57.2M in revenue over the trailing twelve months, down 62.05% year over year.

• How do I buy stock in Cellectis (CLLS)?

  CLLS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.